Assertio Therapeutics, Inc.
100 South Saunders Road, Suite 300
Lake Forest
Illinois
60045
United States
Tel: 224-419-7106
Fax: 510-744-8001
Website: http://www.assertiotx.com/
About Assertio Therapeutics, Inc.
Assertio reflects an aspirational mindset that is forward thinking, energetic, and entrepreneurial in spirit. The Assertio mission of advancing patient care is reflected in our three-pillar strategy:
Maintain
Grow
Build
Maintain
In December 2017, the Company announced the signing of a definitive Commercialization Agreement with Collegium Pharmaceutical under which Collegium will commercialize the NUCYNTA pain franchise and Assertio will receive a royalty rate on all NUCYNTA revenues based on certain net sales thresholds.
Our long-term strategy is to continue to identify, license, develop and market distinctive products that offer enhanced therapeutic options for patients in need—all while maintaining the highest ethical standards in all our business practices.
We have developed and are licensing Acuform® technology, a patented oral delivery technology that allows for targeted, extended release of compounds into the upper GI tract. Acuform is currently utilized in four marketed products, including NUCYNTA ER and Gralise. To date, we’ve also licensed Acuform to six partners
Grow
We currently market three FDA-approved products for various neurological conditions.
Build
We have created a new specialty products business unit, with the objective of assembling a portfolio of specialty/orphan drugs that address the unmet needs of patients, physicians and payers. Our initial focus is the development of Cosyntropin (synthetic ACTH depot), a unique, late-stage product that, upon approval, will provide U.S. patients, physicians and payers with an alternative option.
NASDAQ: ASRT
65 articles about Assertio Therapeutics, Inc.
-
Assertio to Present at LD Micro Invitational Conference in New York City
4/1/2024
Assertio Holdings, Inc. today announced that Ajay Patel, Chief Financial Officer, will present at the LD Micro Invitational XIV Conference to be held April 9, 2024 in New York City.
-
Assertio Holdings, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024
2/29/2024
Assertio Holdings, Inc. announced that it will release fourth quarter and full year 2023 financial results on Monday, March 11, 2024, after the market close.
-
Assertio Holdings, Inc. Appoints Sravan Emany to Its Board of Directors
11/14/2023
Assertio Holdings, Inc., a specialty pharmaceutical company that acquires, commercializes and develops safe and effective therapies that make a difference in the lives of patients, announced that Sravan Emany has been appointed to the Company’s Board of Directors.
-
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - October 06, 2023
10/6/2023
Assertio Holdings, Inc., a specialty pharmaceutical company offering differentiated products to patients, announced that effective October 4, 2023, the Compensation Committee of the Company’s Board of Directors granted one newly-hired employee a total of 9,800 restricted stock units and 11,575 stock options.
-
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - August 25, 2023
8/25/2023
Assertio Holdings, Inc. announced that effective August 21, 2023, the Compensation Committee of the Company’s Board of Directors granted one newly-hired employee a total of 11,585 restricted stock units and 12,745 stock options.
-
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - August 08, 2023
8/8/2023
Assertio Holdings, Inc. announced that effective July 31, 2023, the Compensation Committee of the Company’s Board of Directors granted eight newly-hired employees a total of 82,341 restricted stock units and 92,591 stock options.
-
Assertio Reports Second Quarter 2023 Financial Results, Closes Spectrum Acquisition
8/3/2023
Assertio Holdings, Inc. reported financial results for the second quarter ended June 30, 2023 and provided updates related to the acquisition of Spectrum Pharmaceuticals, Inc., which closed effective July 31, 2023.
-
Assertio Holdings, Inc. Closes Spectrum Pharmaceuticals Transaction
7/31/2023
Assertio Holdings, Inc., a specialty pharmaceutical company offering differentiated products to patients, announced that it has closed the proposed acquisition of Spectrum Pharmaceuticals, Inc., a biopharmaceutical company focused on novel and targeted oncology.
-
Assertio Holdings, Inc. Announces Favorable Vote on Proposed Acquisition of Spectrum Pharmaceuticals
7/27/2023
Assertio Holdings, Inc. announced that its stockholders and the stockholders of Spectrum Pharmaceuticals, Inc., a biopharmaceutical company focused on novel and targeted oncology, have each approved the proposed definitive agreement pursuant to which Assertio will acquire Spectrum in an all-stock and contingent value rights transaction.
-
Assertio Holdings, Inc. to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023
7/24/2023
Assertio Holdings, Inc., a specialty pharmaceutical company offering differentiated products to patients, announced that it will release second quarter 2023 financial results on Thursday, August 3, 2023, after the market close.
-
Assertio Holdings, Inc. Updates First Quarter 2023 Financial Results Call Time to Tuesday, May 9, 2023 at 11:30 am Eastern Time
5/5/2023
Assertio Holdings, Inc., a specialty pharmaceutical company offering differentiated products to patients, announced that it will release first quarter 2023 financial results on Tuesday, May 9, 2023, before the market open.
-
Assertio Holdings, Inc. to Acquire Spectrum Pharmaceuticals, Inc. in All Stock and CVR Transaction
4/25/2023
Assertio Holdings, Inc. and Spectrum Pharmaceuticals, Inc. announced that they have entered into a definitive agreement pursuant to which Assertio will acquire all outstanding shares of Spectrum in an all-stock and contingent value rights transaction.
-
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - April 07, 2023
4/7/2023
Assertio Holdings, Inc. announced that effective April 3, 2023, the Compensation Committee of the Company’s Board of Directors granted two newly-hired employees a total of 20,542 restricted stock units and 24,018 stock options.
-
Assertio Announces Exchange Offer of $30 Million of its Currently Outstanding 6.50% Convertible Senior Notes Due 2027
2/23/2023
Assertio Holdings, Inc. (“Assertio”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced it has entered into separate, privately negotiated exchange agreements (the “Exchange Agreements”) with a limited number of holders of Assertio’s currently outstanding 6.50% Convertible Senior Notes due 2027 (the “Exchanged Notes”).
-
Assertio Holdings, Inc. Announces Preliminary Fourth Quarter and Full Year 2022 Results
2/21/2023
Assertio Holdings, Inc. announced preliminary, unaudited financial results for its fourth quarter and full year 2022, ended December 31, 2022, including its highest quarter of net product sales in the past five years.
-
Assertio to Participate in the 2023 Winter Wonderland Best Ideas Conference
2/16/2023
Assertio Holdings, Inc. announced that Dan Peisert, CEO, and Paul Schwichtenberg, CFO, will host investor meetings Thursday, February 23, 2023 as part of the virtual Third Annual Winter Wonderland Best Ideas Investor Conference.
-
Assertio Holdings, Inc. Announces FDA Orange Book Listing for New Sympazan® Oral Film PatentExtends Intellectual Property Protections to 2039
1/9/2023
Assertio Holdings, Inc. announced that U.S. Patent, No. 11541002 for Sympazan® oral film is now listed in the U.S. Food and Drug Administration publication, Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book.
-
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Jan 06, 2023
1/6/2023
Assertio Holdings, Inc. announced that effective January 3, 2023, the Compensation Committee of the Company’s Board of Directors granted four newly-hired employees a total of 14,804 restricted stock units and 16,001 stock options.
-
Assertio Reports Third Quarter 2022 Financial Results
11/8/2022
Assertio Holdings, Inc., a specialty pharmaceutical company offering differentiated products to patients, reported financial results for the third quarter ended September 30, 2022.
-
Assertio Holdings, Inc. to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
10/27/2022
Assertio Holdings, Inc., a specialty pharmaceutical company offering differentiated products to patients, announced that it will release third quarter 2022 financial results on Tuesday, November 8, 2022, after the market close.